Related references
Note: Only part of the references are listed.Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
Lotte C. A. Stiekema et al.
EUROPEAN HEART JOURNAL (2019)
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies A Mendelian Randomization Analysis
Stephen Burgess et al.
JAMA CARDIOLOGY (2018)
Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice
Xuchu Que et al.
NATURE (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Peter Willeit et al.
LANCET (2018)
PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
Sophie J. Bernelot Moens et al.
EUROPEAN HEART JOURNAL (2017)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo
Siroon Bekkering et al.
ATHEROSCLEROSIS (2016)
Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans
Fleur M. van der Valk et al.
CIRCULATION (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype
Ana Cenarro et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Intensification of Statin Therapy Results in a Rapid Reduction in Atherosclerotic Inflammation Results of a Multicenter Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Feasibility Study
Ahmed Tawakol et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
DAMPening Inflammation by Modulating TLR Signalling
A. M. Piccinini et al.
MEDIATORS OF INFLAMMATION (2010)
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Robert Clarke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury
Yumiko Imai et al.
CELL (2008)
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
PM Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
